Company Description
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
HST Pathways moving headquarters to Nashville - San Francisco Business Times
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
HST Pathways moving headquarters to Nashville - Nashville Business Journal
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026
NASHVILLE, Tenn., April 20, 2021 (GLOBE NEWSWIRE) Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $50 million aggregate principal amount of 8.625% senior notes due 2026 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase an additional $5.0 million aggregate principal amount of Notes in connection with the offering.
Harrow Health and this issuance of notes both received a rating of “BB” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. The Notes are expected to begin trading on Nasdaq under the symbol “HROWL” following the closing date of this offering.
88 Biggest Movers From Yesterday Benzinga 12/24/2020
Gainers
Ocugen, Inc. (NASDAQ: OCGN) shares climbed 222.9% to close at $2.60 on Wednesday after the company announced it will convene its Meeting of Stockholders on Dec. 23 to modify a proposal, decreasing the proposed aggregate number of shares of common stock that the Company would be authorized to issue. Ocugen shares jumped around 174% on Tuesday after the company and Bharat Biotech announced plans to co-develop a whole-virion inactivated COVID-19 vaccine candidate.
Jaguar Health, Inc. (NASDAQ: JAGX) jumped 170.3% to close at $1.07 after the company signed an agreement with a secured lender involving the $6 million sale of royalty interest in Mytesi royalties.